Selective requirement of PI3K/PDK1 signaling for kras oncogene-driven pancreatic cell plasticity and cancer

Cancer Cell

Volumn 23, Issue 3, 2013, Pages 406-420

  Eser, Stefan ^a   Reiff, Nina ^a   Messer, Marlena ^a   Seidler, Barbara ^a   Gottschalk, Kathleen ^a   Dobler, Melanie ^a   Hieber, Maren ^a   Arbeiter, Andreas ^a   Klein, Sabine ^a   Kong, Bo ^a   Michalski, Christoph W ^a   Schlitter, Anna Melissa ^a   Esposito, Irene ^a,e   Kind, Alexander J ^a   Rad, Lena ^b   Schnieke, Angelika E ^a   Baccarini, Manuela ^c   Alessi, Dario R ^d   Rad, Roland ^a,b,e   Schmid, Roland M ^a,e   Schneider, Günter ^a   Saur, Dieter ^a,e   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PICTILISIB;

ACINAR TO DUCTAL METAPLASIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ENGINEERING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METAPLASIA; MOUSE; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

EID: 84876437832     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.01.023     Document Type: Article

References (57)

1. Adams J.R., Xu K., Liu J.C., Agamez N.M., Loch A.J., Wong R.G., Wang W., Wright K.L., Lane T.F., Zacksenhaus E., Egan S.E. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 2011, 71:2706-2717.
2. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17:3112-3126.
3. Aichler M., Seiler C., Tost M., Siveke J., Mazur P.K., Da Silva-Buttkus P., Bartsch D.K., Langer P., Chiblak S., Dürr A., et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J. Pathol. 2012, 226:723-734.
4. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 1997, 7:261-269.
5. Ardito C.M., Grüner B.M., Takeuchi K.K., Lubeseder-Martellato C., Teichmann N., Mazur P.K., Delgiorno K.E., Carpenter E.S., Halbrook C.J., Hall J.C., et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
6. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 2005, 5:921-929.
7. Bardeesy N., Aguirre A.J., Chu G.C., Cheng K.H., Lopez L.V., Hezel A.F., Feng B., Brennan C., Weissleder R., Mahmood U., et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 2006, 103:5947-5952.
8. Blasco R.B., Francoz S., Santamaría D., Cañamero M., Dubus P., Charron J., Baccarini M., Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19:652-663.
9. Caldwell M.E., DeNicola G.M., Martins C.P., Jacobetz M.A., Maitra A., Hruban R.H., Tuveson D.A. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2012, 31:1599-1608.
10. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
11. Carpelan-Holmström M., Nordling S., Pukkala E., Sankila R., Lüttges J., Klöppel G., Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005, 54:385-387.
12. Castellano E., Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer 2011, 2:261-274.
13. Collisson E.A., Trejo C.L., Silva J.M., Gu S., Korkola J.E., Heiser L.M., Charles R.P., Rabinovich B.A., Hann B., Dankort D., et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012, 2:685-693.
14. Conradt L., Godl K., Schaab C., Tebbe A., Eser S., Diersch S., Michalski C.W., Kleeff J., Schnieke A., Schmid R.M., et al. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 2011, 13:1026-1034.
15. Currie R.A., Walker K.S., Gray A., Deak M., Casamayor A., Downes C.P., Cohen P., Alessi D.R., Lucocq J. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem. J. 1999, 337:575-583.
16. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., Ryan D.P., Meyerhardt J.A., Benes C., Settleman J., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 2011, 121:4311-4321.
17. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
18. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
19. Eser S., Messer M., Eser P., von Werder A., Seidler B., Bajbouj M., Vogelmann R., Meining A., von Burstin J., Algül H., et al. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc. Natl. Acad. Sci. USA 2011, 108:9945-9950.
20. Graupera M., Guillermet-Guibert J., Foukas L.C., Phng L.K., Cain R.J., Salpekar A., Pearce W., Meek S., Millan J., Cutillas P.R., et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008, 453:662-666.
21. Guerra C., Schuhmacher A.J., Cañamero M., Grippo P.J., Verdaguer L., Pérez-Gallego L., Dubus P., Sandgren E.P., Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
22. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., Nye E., Stamp G., Alitalo K., Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
23. Hashimoto N., Kido Y., Uchida T., Asahara S., Shigeyama Y., Matsuda T., Takeda A., Tsuchihashi D., Nishizawa A., Ogawa W., et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat. Genet. 2006, 38:589-593.
24. Heid I., Lubeseder-Martellato C., Sipos B., Mazur P.K., Lesina M., Schmid R.M., Siveke J.T. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 2011, 141:719-730.
25. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
26. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
27. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
28. Hruban R.H., Rustgi A.K., Brentnall T.A., Tempero M.A., Wright C.V., Tuveson D.A. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006, 66:14-17.
29. Jesenberger V., Procyk K.J., Rüth J., Schreiber M., Theussl H.C., Wagner E.F., Baccarini M. Protective role of Raf-1 in Salmonella-induced macrophage apoptosis. J. Exp. Med. 2001, 193:353-364.
30. Jimeno A., Tan A.C., Coffa J., Rajeshkumar N.V., Kulesza P., Rubio-Viqueira B., Wheelhouse J., Diosdado B., Messersmith W.A., Iacobuzio-Donahue C., et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 2008, 68:2841-2849.
31. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
32. Karreth F.A., Frese K.K., DeNicola G.M., Baccarini M., Tuveson D.A. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov 2011, 1:128-136.
33. Kennedy A.L., Morton J.P., Manoharan I., Nelson D.M., Jamieson N.B., Pawlikowski J.S., McBryan T., Doyle B., McKay C., Oien K.A., et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol. Cell 2011, 42:36-49.
34. Lawlor M.A., Mora A., Ashby P.R., Williams M.R., Murray-Tait V., Malone L., Prescott A.R., Lucocq J.M., Alessi D.R. Essential role of PDK1 in regulating cell size and development in mice. EMBO J. 2002, 21:3728-3738.
35. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
36. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., Yang J., Semaan D.J., Chen C., Fox E.A., et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 2011, 17:1116-1120.
37. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M.X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 2011, 17:6437-6447.
38. Means A.L., Meszoely I.M., Suzuki K., Miyamoto Y., Rustgi A.K., Coffey R.J., Wright C.V., Stoffers D.A., Leach S.D. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 2005, 132:3767-3776.
39. Morris J.P., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 2010, 10:683-695.
40. Muzumdar M.D., Tasic B., Miyamichi K., Li L., Luo L. A global double-fluorescent Cre reporter mouse. Genesis 2007, 45:593-605.
41. Nakhai H., Sel S., Favor J., Mendoza-Torres L., Paulsen F., Duncker G.I., Schmid R.M. Ptf1a is essential for the differentiation of GABAergic and glycinergic amacrine cells and horizontal cells in the mouse retina. Development 2007, 134:1151-1160.
42. Navas C., Hernández-Porras I., Schuhmacher A.J., Sibilia M., Guerra C., Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:318-330.
43. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
44. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 2010, 11:9-22.
45. Pinho A.V., Rooman I., Reichert M., De Medts N., Bouwens L., Rustgi A.K., Real F.X. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 2011, 60:958-966.
46. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
47. Reichert M., Rustgi A.K. Pancreatic ductal cells in development, regeneration, and neoplasia. J. Clin. Invest. 2011, 121:4572-4578.
48. Reichert M., Saur D., Hamacher R., Schmid R.M., Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res. 2007, 67:4149-4156.
49. Seidler B., Schmidt A., Mayr U., Nakhai H., Schmid R.M., Schneider G., Saur D. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc. Natl. Acad. Sci. USA 2008, 105:10137-10142.
50. Srinivasan L., Sasaki Y., Calado D.P., Zhang B., Paik J.H., DePinho R.A., Kutok J.L., Kearney J.F., Otipoby K.L., Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586.
51. Stanger B.Z., Stiles B., Lauwers G.Y., Bardeesy N., Mendoza M., Wang Y., Greenwood A., Cheng K.H., McLaughlin M., Brown D., et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8:185-195.
52. von Burstin J., Eser S., Seidler B., Meining A., Bajbouj M., Mages J., Lang R., Kind A.J., Schnieke A.E., Schmid R.M., et al. Highly sensitive detection of early-stage pancreatic cancer by multimodal near-infrared molecular imaging in living mice. Int. J. Cancer 2008, 123:2138-2147.
53. von Burstin J., Eser S., Paul M.C., Seidler B., Brandl M., Messer M., von Werder A., Schmidt A., Mages J., Pagel P., et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009, 137:361-371.
54. von Werder A., Seidler B., Schmid R.M., Schneider G., Saur D. Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. Nat. Protoc. 2012, 7:1167-1183.
55. Westmoreland J.J., Wang Q., Bouzaffour M., Baker S.J., Sosa-Pineda B. Pdk1 activity controls proliferation, survival, and growth of developing pancreatic cells. Dev. Biol. 2009, 334:285-298.
56. Ying H., Elpek K.G., Vinjamoori A., Zimmerman S.M., Chu G.C., Yan H., Fletcher-Sananikone E., Zhang H., Liu Y., Wang W., et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov 2011, 1:158-169.
57. Yuan W., Stawiski E., Janakiraman V., Chan E., Durinck S., Edgar K.A., Kljavin N.M., Rivers C.S., Gnad F., Roose-Girma M., et al. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 2013, 32:318-326.